JPWO2023027198A1 - - Google Patents
Info
- Publication number
- JPWO2023027198A1 JPWO2023027198A1 JP2022574839A JP2022574839A JPWO2023027198A1 JP WO2023027198 A1 JPWO2023027198 A1 JP WO2023027198A1 JP 2022574839 A JP2022574839 A JP 2022574839A JP 2022574839 A JP2022574839 A JP 2022574839A JP WO2023027198 A1 JPWO2023027198 A1 JP WO2023027198A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023048827A JP7466731B2 (ja) | 2021-11-24 | 2023-03-24 | トリアジン誘導体を含有する経口投与する製剤 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021189932 | 2021-11-24 | ||
| JP2021189932 | 2021-11-24 | ||
| JP2021191635 | 2021-11-26 | ||
| JP2021191635 | 2021-11-26 | ||
| JP2022006725 | 2022-01-19 | ||
| JP2022006725 | 2022-01-19 | ||
| JP2022012386 | 2022-01-28 | ||
| JP2022012386 | 2022-01-28 | ||
| JP2022017132 | 2022-02-07 | ||
| JP2022017132 | 2022-02-07 | ||
| JP2022027629 | 2022-02-25 | ||
| JP2022027629 | 2022-02-25 | ||
| JP2022046304 | 2022-03-23 | ||
| JP2022046304 | 2022-03-23 | ||
| JP2022142767 | 2022-09-08 | ||
| JP2022142767 | 2022-09-08 | ||
| CN202211151791.9 | 2022-09-21 | ||
| CN202211151791.9A CN116514734A (zh) | 2021-11-24 | 2022-09-21 | 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂 |
| PCT/JP2022/043092 WO2023027198A1 (ja) | 2021-11-24 | 2022-11-22 | トリアジン誘導体を含有する経口投与する製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023048827A Division JP7466731B2 (ja) | 2021-11-24 | 2023-03-24 | トリアジン誘導体を含有する経口投与する製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023027198A1 true JPWO2023027198A1 (https=) | 2023-03-02 |
| JP7253866B1 JP7253866B1 (ja) | 2023-04-07 |
| JPWO2023027198A5 JPWO2023027198A5 (https=) | 2023-08-02 |
Family
ID=85321709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574839A Active JP7253866B1 (ja) | 2021-11-24 | 2022-11-22 | トリアジン誘導体を含有する経口投与する製剤 |
| JP2023048827A Active JP7466731B2 (ja) | 2021-11-24 | 2023-03-24 | トリアジン誘導体を含有する経口投与する製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023048827A Active JP7466731B2 (ja) | 2021-11-24 | 2023-03-24 | トリアジン誘導体を含有する経口投与する製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240148741A1 (https=) |
| EP (1) | EP4289432A4 (https=) |
| JP (2) | JP7253866B1 (https=) |
| KR (1) | KR20230119022A (https=) |
| AU (1) | AU2022333823A1 (https=) |
| WO (1) | WO2023027198A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| LT4122926T (lt) | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| EP4289432A4 (en) * | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
| WO2023054732A2 (ja) * | 2022-01-19 | 2023-04-06 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
| US11655240B1 (en) * | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
| WO2023193818A1 (zh) * | 2022-04-08 | 2023-10-12 | 湖北九康通生物医药有限公司 | 一种多取代三嗪烷类化合物的合成方法 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| CN116554106A (zh) * | 2023-04-28 | 2023-08-08 | 扬州市普林斯医药科技有限公司 | 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法 |
| CN116589410B (zh) * | 2023-05-29 | 2024-05-03 | 济南国鼎医药科技有限公司 | 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法 |
| CN116621817B (zh) * | 2023-07-20 | 2023-09-29 | 爱斯特（成都）生物制药股份有限公司 | 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途 |
| CN117357531A (zh) * | 2023-09-08 | 2024-01-09 | 湖北九康通生物医药有限公司 | 一种药物组合物、其制备方法和其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| PL2399910T3 (pl) * | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| CN103153968B (zh) | 2010-08-10 | 2016-02-03 | 盐野义制药株式会社 | 三唑衍生物及含有其的具有镇痛作用的药物组合物 |
| TW201331188A (zh) | 2011-12-15 | 2013-08-01 | Shionogi & Co | 經取代之三□衍生物及含有其之醫藥組成物 |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| WO2019087884A1 (ja) * | 2017-10-31 | 2019-05-09 | 富士フイルム株式会社 | 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー |
| PH12021552872A1 (en) | 2020-04-05 | 2022-03-21 | Pfizer | Compounds and methods for the treatment of covid-19 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4282420A4 (en) * | 2021-01-20 | 2024-11-27 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| EP4313097A4 (en) * | 2021-03-29 | 2025-03-19 | Shireen Nature Company for General Trading, Ltd. | Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions |
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| CN113801097B (zh) | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113666914B (zh) | 2021-09-27 | 2022-06-07 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
| CN113773300B (zh) | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | 磺酰胺类化合物、其制备方法及用途 |
| CN113735838B (zh) | 2021-09-27 | 2022-07-08 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113620888B (zh) | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和应用 |
| EP4289432A4 (en) | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
-
2022
- 2022-11-22 EP EP22861484.8A patent/EP4289432A4/en active Pending
- 2022-11-22 WO PCT/JP2022/043092 patent/WO2023027198A1/ja not_active Ceased
- 2022-11-22 US US18/277,445 patent/US20240148741A1/en active Pending
- 2022-11-22 JP JP2022574839A patent/JP7253866B1/ja active Active
- 2022-11-22 KR KR1020237025438A patent/KR20230119022A/ko active Pending
- 2022-11-22 AU AU2022333823A patent/AU2022333823A1/en active Pending
-
2023
- 2023-03-24 JP JP2023048827A patent/JP7466731B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230119022A (ko) | 2023-08-14 |
| JP7253866B1 (ja) | 2023-04-07 |
| AU2022333823A1 (en) | 2024-05-02 |
| WO2023027198A1 (ja) | 2023-03-02 |
| JP7466731B2 (ja) | 2024-04-12 |
| US20240148741A1 (en) | 2024-05-09 |
| EP4289432A4 (en) | 2025-01-15 |
| EP4289432A1 (en) | 2023-12-13 |
| JP2023078413A (ja) | 2023-06-06 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221205 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20221205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230301 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230324 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7253866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |